Search bioRxiv⌕ Search

Biology subjects

Rovers, E.

Publications and source records attributed to Rovers, E..

2 recordsLinked to original sources

Benchmarking PROTAC docking and virtual screening tools

Proteolysis targeting chimeras (PROTACs) are bifunctional compounds that recruit an E3 ligase to a target protein to induce ubiquitination and degradation of the target and are pioneer molecules in the field of proximity pharmacology. Rational PROTAC design is a challenging process and novel computational tools have emerged that attempt to predict the ternary complexes created by PROTACs and identify PROTAC candidates. To compare the performance of recent PROTAC design and screening methods, a benchmark was developed to test the ability of these tools to 1) predict the ternary complexes observed in crystal structures and 2) dissociate active from inactive PROTACs. Unlike traditional protein-protein complex prediction software, the PROTAC virtual screening methods often generate successfully PROTAC-induced protein complex structures observed crystallographically, but these experimentally validated predictions are not dissociated from dozens or more of other predicted structures. PROTAC virtual screening efficiency is unclear and highly variable, in part due to the limited size of experimental datasets and the low number of negative controls. Defining ubiquitination zones within cullin-RING complexes does not improve predictions, but conformational arrangements can sometimes be found that are exclusively associated with active PROTACs. Computer assisted PROTAC design is still in its infancy. Pioneering tools highlight the promises and challenges in the field and may be more valuable when guided by clear structural and biophysical data and validated on specific chemical series.

bioinformatics↗

Structure-Based Survey of the Human Proteome for Opportunities in Proximity Pharmacology

Proximity pharmacology (ProxPharm) is a novel paradigm in drug discovery where a small molecule brings two proteins in close proximity to elicit a signal, generally from one protein onto another. The potential of ProxPharm compounds as a new therapeutic modality is firmly established by proteolysis targeting chimeras (PROTACs) that bring an E3 ubiquitin ligase in proximity to a target protein to induce ubiquitination and subsequent degradation of the target protein. The concept can be expanded to induce other post-translational modifications via the recruitment of different types of protein-modifying enzymes. To survey the human proteome for opportunities in proximity pharmacology, we systematically mapped non-catalytic drug binding pockets on the structure of protein-modifying enzymes available from the Protein Databank. In addition to binding sites exploited by previously reported ProxPharm compounds, we identified putative ligandable non-catalytic pockets in 188 kinases, 42 phosphatases, 26 deubiquitinases, 9 methyltransferases, 7 acetyltransferases, 7 glycosyltransferases, 4 deacetylases, 3 demethylases and 2 glycosidases, including cavities occupied by chemical matter that may serve as starting points for future ProxPharm compounds. This systematic survey confirms that proximity pharmacology is a versatile modality with largely unexplored and promising potential, and reveals novel opportunities to pharmacologically rewire molecular circuitries.

bioinformatics↗